ND-646 NEW
| Price | $59 | $197 | $322 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: ND-646 | CAS No.: 1434639-57-2 |
| Purity: 99.65% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | ND-646 |
| Description | ND-646 is an orally bioavailable and allosteric inhibitor of the ACC enzymes ACC1 and ACC2, with IC50 values of 3.5 nM and 4.1 nM for recombinant hACC1 and hACC2, respectively. |
| In vivo | ND-646-an allosteric inhibitor of the ACC enzymes ACC1 and ACC2 that prevents ACC subunit dimerization-to suppress fatty acid synthesis in vitro and in vivo.?Chronic ND-646 treatment of xenograft and genetically engineered mouse models of NSCLC inhibited tumor growth.?When administered as a single agent or in combination with the standard-of-care drug carboplatin, ND-646 markedly suppressed lung tumor growth in the Kras;Trp53-/- (also known as KRAS p53) and Kras;Stk11-/- (also known as KRAS Lkb1) mouse models of NSCLC. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 10 mg/mL (17.59 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 150 mg/mL (263.79 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (17.59 mM), Solution. |
| Keywords | ND-646 | ND646 | ND 646 | Inhibitor | inhibit | AcetylCoACarboxylase | Acetyl-CoA Carboxylase | AcetylCoA Carboxylase | ACC, Acetyl Coenzyme A Carboxylase | ACC |
| Inhibitors Related | Alisol A | CMS-121 | Cyhalofop-butyl | Acetyl-CoA Carboxylase-IN-1 | Firsocostat | PF-05221304 | Clethodim | Clodinafop-propargyl | VY-3-135 | Quizalofop-ethyl | TOFA | Tralkoxydim |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Cardiovascular Disease Compound Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Preclinical Compound Library | Anti-Hypertension Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:26383-05-1
-
CAS:849241-79-8
-
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY